Table 1.
Marrow to Muscle and Lung Conversions
| Tissue | Injury | Donor Cells | Conversion Result Tissue Cells (%) |
Reference |
|---|---|---|---|---|
|
Skeletal Muscle |
Radiation & exercise | GFP- marrow | 3.5% (peak) | 80 |
| TBI/mdx Mouse | Spleen & marrow | 0.2% (approx) | 81 | |
| TBI/mdx Mouse | Marrow side population |
1–10% | 82 | |
| TBI/cardiotoxin injury anterior tibialis |
GFP-marrow Intra-arterial |
1–2% | 83 | |
| (+direct injection of lineage negative marrow cells) |
12.5% | 84 | ||
| Alpha-Sarcoglycan null dystrophic mice |
mesangioblast stem cells |
50% | 85 | |
| Lung | 700–950 cGy | GFP marrow, mononuclear cells or side population |
1–7% (mixed population, type I pneumocytes) |
86 |
| Non-irradiated |
Rosa MAPC | 3–5% |
87 | |
| (+250 cGy) | (10%) | |||
| 1050 cGy | Fr25/Lin- | 20% type II pneumocytes |
88 | |
| 900 cGy, cardiotoxin or bleomycin lung injury with G-CSF mobilization (x2) |
Cytokine treated GFP marrow |
35% (peak) | 89 | |
TBI: total body irradiation; Mdx: dystrophin deficient mouse